Advertisement

The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system

  • Patrick Fitzgerald
  • Fred Kusumoto
Article
  • 12 Downloads

Abstract

AV conduction abnormalities are observed in 15–30% of patients with hypertrophic cardiomyopathy but are usually not severe enough to require permanent pacemaker implant. Both septal myectomy and alcohol septal ablation are effective options to relieve symptoms due to left ventricular outflow tract gradient in patients with hypertrophic cardiomyopathy but have procedure-specific effects on AV conduction and the His Purkinje system. Septal myectomy is associated with the development of LBBB in 50–100% of patients, while alcohol septal ablation is associated with RBBB in 37–70% of patients. Baseline abnormalities in the contralateral bundles and the presence of conduction disease have an important impact on the likelihood of the development of AV block for both of these therapies. AV block requiring permanent pacing occurs in approximately 2–3% of patients after septal myectomy and 10–15% of patients after alcohol septal ablation. Permanent pacemaker implant after alcohol septal ablation is more common in older patients (> 55 years old 13 vs. < 55 years old 5%; p = 0.06). Improved outcomes for septal myectomy and alcohol septal ablation are observed in experienced centers. Septal reduction therapies should be performed at medical centers with a dedicated hypertrophic cardiomyopathy program using a multidisciplinary approach.

Keywords

Hypertrophic cardiomyopathy Septal myectomy Alcohol septal ablation Pacemaker Bundle branch block 

References

  1. 1.
    Teare D Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20(1):1–8.Google Scholar
  2. 2.
    Bercu BA, Diettert GA, Danforth WH, Pund EE Jr, Ahlvin RC, Belliveau RR. Pseudoaortic stenosis produced by ventricular hypertrophy. Am J Med. 1958;25(5):814.CrossRefPubMedGoogle Scholar
  3. 3.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2011;124(24):e783–831.CrossRefPubMedGoogle Scholar
  4. 4.
    Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO 3rd, Bonow RO, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989;80(5):1259–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697–704.CrossRefPubMedGoogle Scholar
  6. 6.
    Barriales-Villa R, Centurión-Inda R, Fernández-Fernández X, Ortiz MF, Pérez-Alvarez L, Rodríguez García I, et al. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2010;63(8):985–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Doven O, Cicek D, Pekdemir H, Camsari A, Parmaksiz T, Cin GV, et al. Abnormal His-Purkinje system conduction leading to complete atrioventricular block in patients with hypertrophic cardiomyopathy: a report of 3 cases. Jpn Heart J. 2004;45(2):347–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Bahl A, Saikia UN, Talwar KK. Familial conduction system disease associated with hypertrophic cardiomyopathy. Int J Cardiol. 2008;125(3):e44–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Grall S, Biere L, Clerfond G, Mateus V, Prunier F, Furber A. ECG characteristics according to the presence of late gadolinium enhancement on cardiac MRI in hypertrophic cardiomyopathy. Open Heart. 2014;1(1):e000101.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaorticventriculomyotomy. Ann Surg. 1961;154:181–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kirklin JW, Ellis FH Jr. Surgical relief of diffuse subvalvular aortic stenosis. Circulation. 1961;24:739–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Brock R. Aortic subvalvar stenosis: surgical treatment. Guys Hosp Rep. 1959;108:144–58.PubMedGoogle Scholar
  14. 14.
    Nguyen A, Schaff HV, Nishimura RA, Dearani JA, Geske JB, Lahr BD, et al. Does septal thickness influence outcome of myectomy for hypertrophic obstructive cardiomyopathy? Eur J Cardiothorac Surg. 2018;53(3):582–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Kotkar KD, Said SM, Dearani JA, Schaff HV. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann Cardiothorac Surg. 2017;6(4):329–36.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Fifer MA, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J. 2011;32(9):1059–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Yuan J, Qiao S, Zhang Y, You S, Duan F, Hu F, et al. Follow-up by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy who underwent percutaneous ventricular septal ablation. Am J Cardiol. 2010;106(10):1487–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49(3):350–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Hamatani Y, Amaki M, Kanzaki H, Yamashita K, Nakashima Y, Shibata A, et al. Contrast-enhanced computed tomography with myocardial three-dimensional printing can guide treatment in symptomatic hypertrophic obstructive cardiomyopathy. ESC Heart Fail. 2017;4(4):665–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chan W, Williams L, Kotowycz MA, Woo A, Rakowski H, Schwartz L, et al. Angiographic and echocardiographic correlates of suitable septal perforators for alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2014;30(8):912–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang S, Luo M, Sun H, Song Y, Yin C, Wang L, et al. A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic cardiomyopathy in China. Eur J Cardiothorac Surg. 2013;43(3):534–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ, et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44(12):2329–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Qin JX, Shiota T, Lever HM, Asher CR, Popović ZB, Greenberg NL, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol. 2004;93(2):171–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, Desai MY. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg. 2010;140(2):317–24.CrossRefPubMedGoogle Scholar
  26. 26.
    Lai Y, Guo H, Li J, Dai J, Ren C, Wang Y. Comparison of surgical results in patients with hypertrophic obstructive cardiomyopathy after classic or modified morrow septal myectomy. Medicine (Baltimore). 2017;96(51):e9371.CrossRefGoogle Scholar
  27. 27.
    Liebregts M, Steggerda RC, Vriesendorp PA, van Velzen H, Schinkel AF, Willems R, et al. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC Cardiovasc Interv. 2016;9(5):463–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Runquist LH, Nielsen CD, Killip D, Gazes P, Spencer WH 3rd. Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2002;90(9):1020–2.CrossRefPubMedGoogle Scholar
  29. 29.
    Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119(2):163–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Coakley E, Steinberg DH, Tibrewala A, Asch F, Pichard AD, Kent KM, et al. Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on the electrocardiographic pattern. Am J Cardiol. 2008;102(5):621–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Gomes OM, Coelho AA, Osterne EC, Abrantes RD. Coronary morphology and conduction system disturbance induced by therapeutic embolization of the coronary septal artery. Heart Surg Forum. 2010;13(1):E45–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Durand E, Mousseaux E, Coste P, Pillière R, Dubourg O, Trinquart L, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J. 2008;29(3):348–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Guerrero I, Dhoble A, Fasulo M, Denktas AE, Sami S, Choi S, et al. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2016;88(6):971–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3(11):896–905.CrossRefPubMedGoogle Scholar
  35. 35.
    Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55(8):823–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal Myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide inpatient database, 2003-2011. JAMA Cardiol. 2016;1(3):324–32.CrossRefPubMedGoogle Scholar
  37. 37.
    Veselka J, Faber L, Jensen MK, Cooper R, Januska J, Krejci J, et al. Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2018;34(1):16–22.CrossRefPubMedGoogle Scholar
  38. 38.
    Veselka J, Lawrenz T, Stellbrink C, Zemanek D, Branny M, Januska J, et al. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2013;29(11):1415–21.CrossRefPubMedGoogle Scholar
  39. 39.
    Schuller JL, Zipse MM, Krantz MJ, Blaker B, Salcedo E, Groves BM, et al. Incidence and predictors of late complete heart block after alcohol septal ablation treatment of hypertrophic obstructive cardiomyopathy. J Interv Cardiol. 2015;28(1):90–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2017.  https://doi.org/10.1016/j.hrthm.2017.10.035.
  41. 41.
    McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28(21):2583–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Van Dijk VF, Liebregts M, Luermans JG, Balt JC. Inappropriate shock due to T-wave oversensing by a subcutaneous ICD after alcohol septal ablation for hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(3):307–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Crossen K, Jones M, Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2016;13(9):1885–90.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiovascular DiseaseMayo ClinicJacksonvilleUSA
  2. 2.Division of Cardiology, Department of MedicineUniversity of FloridaGainesvilleUSA

Personalised recommendations